Boston Scientific Corporation BSX recently announced receipt of the FDA’s approval for its TheraSphere Y-90 Glass Microspheres, which have been developed for the treatment of hepatocellular carcinoma ...

Boston Scientific Corporation BSX recently announced favorable study outcome of the TARGET study of its TheraSphere Y-90 Glass Microspheres (TheraSphere) therapy during a late-breaking clinical trial ...

MILWAUKEE (WITI) -- A local man who built a multimedia empire from the ground up is now broadcasting the benefits of a relatively new cancer treatment. For more than 50 years, Vic Eliason has been a ...

OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced that for the ...

Nordion announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere , Nordion's yttrium-90, or Y-90, glass microsphere treatment for liver cancer. The YES-P trial will be ...

The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable ...

(RTTNews) - Boston Scientific Corp. (BSX) said that late-breaking data demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston ...

MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a ...

NICE has issued guidance recommending the use of TheraSphere Y-90 Glass Microspheres, from Boston Scientific, as a treatment for patients with HCC. The National Institute for Health and Care ...

(RTTNews) - Boston Scientific Corp. (BSX) Thursday announced positive data from study of the TheraSphere Y-90 Glass Microspheres, a type of radioembolization comprised of millions of microscopic glass ...

Nordion said today it will sell its liver cancer drug to U.K.-based BTG for $200 million cash, leaving the Canadian company with its specialty medical isotope business four months after it launched a ...